T-ed up.

This secondary analysis of a prospective trial of Pfizer’s COVID-19 vaccine in patients with solid cancers uniquely demonstrates that, while B-cell (i.e., humoral) response is predictably diminished with receipt of chemotherapy, the much less often measured T-cell (i.e., cellular) response remains robust, which is a particularly important safeguard against the Omicron variant and also reinforces the limited clinical utility of antibody testing. | Waldhorn, JAMA Oncol 2022